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Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of
arthritis and psoriasis. PsA runs a variable course, from mild synovitis to severe, progressive,
erosive arthropathy. The pathogenesis of PsA involves alteration in the components of the immune
response, although the exact cause of PsA is unknown. A number of patients with severe peripheral
arthritis fail to respond to standard conventional therapy. Advances in biotechnology and in our
understanding of the immunopathogenesis of PsA have led to great interest and progress in regards
to biologic treatments for PsA. Notable success achieved with recently introduced biologic
therapies has paved the way for further research and develpoment of additional therapies that
should improve outcomes for affected patients.
Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory
arthropathy characterized by the association of arthritis
and psoriasis. Joint involvement is heterogeneous, and
may consist of spondyloarthropathy, as well as oligoartic-
ular and polyarticular peripheral arthritis. PsA runs a var-
iable course, from mild synovitis to severe, progressive,
erosive arthropathy. PsA is classified as one of the sub-
types of spondyloarthropathy, sharing clinical features
such as asymmetric joint involvement, an oligoarticular
arthritis pattern, a similar frequency in men and women,
the common occurrence of enthesitis and dactylitis, infre-
quent rheumatoid factor and anti-cyclic-citrullinated-pep-
tide seropositivity, and extra-articular manifestations such
as iritis.
Epidemiology
Psoriasis occurs in about 2% of the population [1]. PsA
has been reported in 7% to 42% of patients with psoriasis
[2]. The prevalence of PsA in the US has been estimated as
0.67% [3]. However, estimates of prevalence are variable,
due in part to the heterogeneity of the disease as well as a
lack of validated diagnostic criteria [4].
In general, skin involvement precedes joint disease, often
by years. However, PsA precedes skin psoriasis in about
15% of patients, and the two occur simultaneously in
about 20%. Some reports suggest that PsA is more com-
mon in patients with severe psoriasis [5,6]. A recent study
suggested a correlation between the extent of skin and
joint severity only among patients with simultaneous
onset of skin and joint manifestations [7].
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Pathogenesis
The exact cause of PsA is unknown, although genetic,
environmental, and immunologic factors clearly play
important roles. The pathogenic connection between pso-
riasis and arthritis is not clear, although both are immu-
nologically mediated.
Genetic factors
Most studies document a familial predisposition to both
psoriasis and PsA. More than 40% of patients with PsA
have first degree family members with either skin or joint
disease [8,9]. Several genetic susceptibility loci have been
proposed, with the strongest effect residing within the
major histocompatibility complex (MHC). Population
studies in PsA have shown increased frequency of HLA-
B13, B17, B27, B38, B39, DR4 and DR7 [8,10,11]. In a
comparison of 158 patients with PsA to 101 patients with
uncomplicated psoriasis, HLA-B7 and B27 were more
common among patients with PsA, whereas B17, Cw6
and DR7 were more common among patients with
uncomplicated psoriasis [8]. Some of these associations
may be confounded by linkage disequilibrium. HLA-B27
has been associated with spinal disease in which radiolog-
ical sacroiliitis is present. A symmetric pattern of periph-
eral PsA appears related to HLA-DR4 [8,12]. The strongest
susceptibility locus for psoriasis is on chromosome 6p,
termed PSORS1 [1,13-16]. Other psoriasis susceptibility
loci are located on chromosomes 17q25 (PSORS2), 4q34
(PSORS3), 1q (PSORS4), 3q21 (PSORS5), 19p13
(PSORS6), 1p (PSORS7), and 17q25 (RUNX1) [1].
Other genes within the MHC region and non-HLA associ-
ations have been explored. A TNF-α promoter polymor-
phism or a gene in linkage disequilibrium with TNF-α
may predispose or increase susceptibility to psoriasis and
PsA [17]. One study looking at the TNFβ+252 and TNFα-
308 polymorphisms did not find the alleles more fre-
quently in PsA patients than matched controls, but did
find both alleles were significantly associated with the
presence of joint erosions and the progression of joint
erosions in early PsA [18]. A meta-analysis showed the
TNFα-238 variant in Caucasian PsA patients was a signifi-
cant risk factor for PsA [19]. A recent study pointed to Cw6
and MHC class I chain-related A (MICA)-A9 as being the
strongest genetic susceptibility factors for PsA [20].
Environmental factors – infection, trauma
Both viral and bacterial infections have been implicated as
causative agents in PsA. Support for the role of bacterial
antigens in the pathogenesis of psoriasis and PsA comes
from indirect observation of enhanced humoral and cel-
lular immunity to gram-positive bacteria typically found
in the psoriatic plaques [21]. However, psoriatic plaques
often get secondarily infected, thus the cause-effect rela-
tionship of bacteria and psoriasis is difficult to prove. One
study of sera from patients with PsA showed higher levels
of antibody to streptococcal exotoxin, which provides
some evidence of a link between streptococcal infection
and articular inflammation [22]. The possibility that PsA
might be virally induced has been proposed, although
never confirmed [23,24]. Physical trauma may result in
the onset of psoriasis (Koebner Phenomenon) and, theo-
retically, PsA at the sites of injury. This association would
highlight potential association between innate and spe-
cific immunity. There are a number of case reports sug-
gesting a possible role for trauma in PsA, but this has not
been evaluated in a prospective manner.
Immunologic factors
Both psoriasis and PsA are immunologically mediated.
Characteristic pathologic features of PsA are synovial lin-
ing layer cell hyperplasia, inflammatory cell accumulation
and prominent vascularity. T lymphocytes, particularly
CD8+ cells, may play important pathogenic roles. Acti-
vated T cells have been noted in affected tissue, both skin
and joint [25,26]. A predominance of CD8+ T lym-
phocytes with clonal expansion have been found in PsA
synovial fluid leading to the proposal that CD8+ T cells
drive the immune response [27]. This is further supported
by the fact that CD8+ T cells also dominate the infiltrate
at marrow sites adjacent to entheseal inflammation, an
early area of involvement [28]. An analysis of T cell recep-
tor beta chain variable (TCRβV) gene repertoires revealed
common expansions in both skin and synovial inflamma-
tory sites, suggesting an important role for cognate T cell
responses in the pathogenesis of PsA and that the inciting
antigen may be identical or homologous between afflicted
skin and synovium [29].
The cytokine network in the psoriatic skin and synovium
is dominated by monocyte and T-cell derived cytokines:
IL-1β, IL-2, IL-10, IFN-γ and TNF-α [30]. In PsA synovium,
higher levels of IFN-γ, IL-2 and IL-10 have been detected
than in psoriatic skin. One study of cytokine staining in
PsA synovium showed IL-1α, IL-1β, IL-8, IL-15, IFN-γ and
TNF-α staining localized to the lining layer and perivascu-
lar macrophages [31]. These cytokines can induce prolif-
eration and activation of synovial and epidermal
fibroblasts, leading to fibrosis in patients with longstand-
ing PsA. TNF-α, a key proinflammatory cytokine, induces
the production of other inflammatory cytokines such as
IL-1, IL-6, and granulocyte-macrophage colony-stimulat-
ing factor, chemokines such as IL-6, degradative enzymes
such as several matrix metalloproteinases (MMPs) and
other factors. TNF-α mediates a number of biological
processes that can result in joint damage including stimu-
lation of bone resorption, inhibition of bone formation,
and inhibition of synthesis of proteoglycans [32,33]. Ang-
iogenic factors such as TNF-α and vascular endothelialJournal of Immune Based Therapies and Vaccines 2005, 3:6 http://www.jibtherapies.com/content/3/1/6
Page 3 of 9
(page number not for citation purposes)
growth factor (VEGF) may contribute to vascular prolifer-
ation [34,35].
While the mechanisms governing psoriatic skin and joint
involvement are similar, there are distinctions. For exam-
ple, cutaneous lymphocyte associated (CLA) antigen, an
adhesion molecule that identifies lymphocytes that pref-
erentially traffic to the skin, is upregulated on lym-
phocytes in psoriatic skin but is minimally expressed on
cells in the PsA synovium [36].
Clinical Features
Wright and Moll recognized several patterns of PsA: iso-
lated distal interphalangeal disease, peripheral oligoar-
thritis, peripheral polyarthritis, and spondyloarthropathy.
These clinical phenotypes are not fixed but are inter-
changeable, and individual patients can switch pheno-
types [37]. The most important distinction as regards
outcome appears to be oligo- versus poly-articular joint
involvement.
Extra-articular manifestations of PsA are important
aspects of the disease, the most common is the psoriatic
skin lesion, which may affect all areas of the skin. Dactyli-
tis is typical in PsA and presents as inflammation of the
whole digit, joints and tendon sheaths. Enthesitis, inflam-
mation at the site of tendon, ligament or synovial mem-
brane insertion into bone, is characteristic of PsA and may
represent the earliest site of involvement. Other extra-
articular manifestations include the presence of iritis,
mouth ulcers, and urethritis.
PsA has several characteristic radiographic features which
include lack of periarticular osteopenia, destruction of
interphalangeal joints with widening of the joint spaces,
pencil-in-cup changes in the hands and feet, ankylosis,
periosteal reaction, and spur formation [38].
The course of PsA is variable. Patients who have five or
more involved joints at presentation are more likely to
have progressive disease. Some patients have few episodes
and completely recover, but recent studies demonstrated
that many patients have persistent and severe courses [39-
41]. Damage in PsA occurs early and progresses over time,
with increasing deformities and limitation of daily activity
[42]. Patients with PsA have increased mortality com-
pared to the general population. More severe disease, as
manifested by higher ESR and radiologic scores at presen-
tation, is a predictive factor of mortality [43].
Treatment of PsA
Conventional treatment
Mild joint symptoms may respond to non-steroidal anti-
inflammatory drugs (NSAIDs) [42]. Systemic steroids can
be used, but may cause side effects and rebound worsen-
ing of psoriasis [44]. Patients who are unresponsive to
NSAID therapy or who have progressive disease may
require disease modifying anti-rheumatic drugs
(DMARDs) (eg methotrexate [MTX], leflunomide, sul-
fasalazine [SSZ], cyclosporine [CsA]).
MTX is considered by many rheumatologists the DMARD
of choice because of its remarkable efficacy in ameliorat-
ing both skin and joint disease, its rapid onset, and its
acceptable safety profile [45,46]. However, 16–30% of
patients treated with MTX discontinue it because of toxic-
ity [47,48]. Leflunomide, an antipyrimidine drug that
interferes with T-cell activation, has been shown to be
effective in improving both joint and skin symptoms [49].
The most common side effects seen with leflunomide are
diarrhea and increased transaminases. SSZ has been
shown to be helpful for peripheral arthritis but not for
axial disease [50]. CSA improves both joint inflammation
and skin lesions in PsA, but is not frequently used because
of its toxicities, the most worrisome being hypertension
and nephrotoxicity [48,51]. Likewise, gold compounds
and other drugs have been reported to ameliorate arthritis
in some PsA patients, but are rarely used secondary to side
effects and toxicities.
Biologic Agents
In recent years, greater understanding of immunopathol-
ogy and advances in biotechnology facilitating the ability
to design and produce novel biologic agents have led to
exciting breakthroughs in the treatment of autoimmune
disease, including psoriasis and PsA [52]. The develop-
ment of novel biologic agents has been further encour-
aged by the unmet need for better treatments and the
positive results with their use in other autoimmune dis-
eases, particularly rheumatoid arthritis (RA). The most
significant experience of the use of biologics in treatment
of PsA is with TNF-α inhibitors.
Tumor necrosis factor-alpha (TNF-α) inhibitors
Given its pro-inflammatory potential and its elevated lev-
els in RA and PsA, TNF-α was identified as an attractive
target for biologic therapies. TNF-α inhibitors have been
used with great success to suppress joint inflammation in
RA, inducing not only marked improvement in the signs
and symptoms of disease, but also substantially improved
functional status and quality of life [53-55]. Additionally,
they have been shown to attenuate the progression of
radiographic joint damage. Adverse effects have been
reported, but in general these agents are well-tolerated.
These encouraging results spurred interest in using TNF-α
inhibitors in PsA. Currently there are three TNF-α inhibi-
tors available: 1) etanercept, a fusion protein consisting of
a dimer of the extracellular portion of the type II TNF
receptor (p75) linked to the Fc portion of IgG1, 2) inflix-
imab, a chimeric monoclonal antibody specific for TNF-α,Journal of Immune Based Therapies and Vaccines 2005, 3:6 http://www.jibtherapies.com/content/3/1/6
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and 3) adalumimab, a human monoclonal antibody spe-
cific for TNF-α.
1. Etanercept
Etanercept has been proven effective for the treatment of
PsA [56,57]. The first double-blind, placebo controlled
clinical trial of etanercept in PsA was in 60 patients with
long-standing disease. The etanercept group showed sig-
nificant improvement in all measures of disease activity
compared with the placebo group at 12 weeks. The pri-
mary endpoint for arthritis activity, the Psoriatic Arthritis
Response Criteria (PsARC), a composite index, was
achieved by 87% versus 23% of the etanercept and pla-
cebo groups respectively [58]. A secondary endpoint was
the American College of Rheumatology composite
response criteria (ACR), a score based on 20%, 50%, or
70% improvement [59]. ACR20 responses were 73% and
13% in the etanercept and placebo groups respectively
[56]. For psoriasis, the primary endpoint was 75%
improvement in the Psoriasis Area and Severity (PASI)
score (PASI75). Of patients with >3% body surface
involvement, 26% of etanercept treated patients achieved
PASI75 versus none in the placebo treated group [56].
Disability, as assessed by responses on the health assess-
ment questionnaire (HAQ), significantly improved in the
etanercept group. An open-label extension of this study
revealed sustained efficacy in joints, further improvement
of skin disease, ability to decrease or discontinue concom-
itant methotrexate and prednisone, and continued tolera-
bility [60].
Another phase III clinical trial of etanercept in 205
patients with PsA confirmed and extended earlier find-
ings. ACR20 response rates were achieved by 59% of the
etanercept group and 15% of the placebo group at 12
weeks (P < 0.001). This clinical response was sustained for
24 weeks. Of those meeting criteria for PASI evaluation,
the etanercept group showed on average 47% improve-
ment compared to no improvement in the placebo group
(P < 0.001) [57].
Etanercept has been observed to slow and halt radio-
graphic structural damage in PsA. A one year study of 205
patients revealed that at twelve months the radiographic
disease progression in the etanercept group was inhibited
(Sharp score: -.03 units) compared with worsening in the
placebo group (Sharp score: +1.00 units) (p = .0001) [61].
2. Infliximab
Open-label studies of infliximab in PsA showed signifi-
cant decreases in the signs and symptoms of joint inflam-
mation and skin disease [62-64]. This led to double blind,
placebo controlled trials, which also revealed positive
results [65,66]. The infliximab multinational psoriatic
arthritis controlled trial (IMPACT) enrolled 104 patients
in a double blind, randomized, placebo-controlled trial
for 16 weeks, followed by blinded single-crossover design
through 50 weeks [65]. ACR20/50/70 responses at week
16 were 69%/49%/29% in the active treatment group
compared to 8%/0%/0% in the placebo group. These
results were sustained at 50 weeks with ACR 20/50/70
responses in the infliximab group of 72%/54%/35%. Of
the placebo-treated patients who crossed over to active
treatment at week 16, ACR20/50/70 responses increased
to 77%/49%/30%. This study also assessed dactylitis and
enthesitis, two important characteristics of PsA that had
not previously been included in clinical trials. Significant
improvements were seen in dactylitis and enthesitis with
infliximab therapy. Of particular note in this study was
the dramatic improvement in skin psoriasis seen with inf-
liximab treatment. Thus, PASI75 was achieved by 12 of 14
infliximab patients whereas there was overall worsening
of skin scores in the placebo treated group. This effect was
sustained at week 50. Also, 8 of 16 placebo patients who
switched to infliximab treatment after week 16 achieved
PASI75 at week 50.
These results were confirmed with the subsequent larger
phase 3 IMPACT 2 study [67]. In this trial, 200 patients
with active PsA were randomized to receive infliximab or
placebo for 24 weeks. ACR 20/50/70 scores at week 24 in
the infliximab group were 54%/41%/27% and 11%/4%/
2% in the placebo group. Again, skin improvement was
very impressive, with 60% of the infliximab group achiev-
ing PASI75 at week 24, whereas only 1% of the placebo
group did. Statistically significant improvements in meas-
ures of functional status and quality of life (measured by
HAQ and SF-36, respectively) were seen, as were improve-
ments in dactylitis and enthesopathy.
Two studies have shown that infliximab can inhibit radi-
ographic disease progression. In a double-blind, placebo
controlled trial of 200 PsA patients (IMPACT2), patients
treated with infliximab had significantly less radiographic
disease progression at week 24, as measured by the van
der Heijde-Sharp method modified for PsA (-0.7 +/- 2.53
versus .82 +/- 2.62, for infliximab versus placebo treated
patients respectively; p < 0.001) [68]. An analysis of
patients from the IMPACT1 study showed that at 50
weeks, radiographic progression of disease was inhibited
in both the group treated with infliximab throughout the
trial as well as in the group receiving infliximab from week
16 through week 50 [69].
3. Adalumimab
Adalumimab was assessed in PsA in a phase III, placebo-
controlled, double blind study, the Adalimumab Effec-
tiveness in PsA Trial (ADEPT) [70]. 151 patient received
adalumimab and 162 received placebo. Adalumimab
treated patients showed rapid improvements. At week 24Journal of Immune Based Therapies and Vaccines 2005, 3:6 http://www.jibtherapies.com/content/3/1/6
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ACR20, 50, and 70 scores for adalumimab were 57%,
39%, and 23% respectively versus 15%, 6%, and 1% for
placebo. PASI50, 75 and 90 scores for adalumimab and
placebo respectively were 75%, 59%, and 42% versus
12%, 1%, and 0% [70].
Adalimumab was also shown to inhibit radiographic dis-
ease progression. In the ADEPT trial, at week 24 mean
change in modified total Sharp Scores (mTSS) was -0.2 in
infliximab treated patients compared with +1.0 in placebo
treated patients (p <= .001). All patients were allowed to
go into an open label extension after week 24. Patients
who started in the placebo arm and crossed to the adali-
mumab open label arm at week 24 had mTSS scores of
+1.0 and +1.0 at weeks 24 and 48 respectively, showing
no further radiographic progression after they started
adalimumab. The patients originally in the adalimumab
arm who extended into open label treatment had mTSS
scores of -0.2 and 0.1 at weeks 24 and 48 respectively.
Assessments at week 48 showed that adalimumab main-
tained the lack of radiographic change [71].
With all TNF-α inhibitors there have been concerns about
safety issues, particularly infections, serious infections
and opportunistic infections such as reactivation of latent
tuberculosis. Appropriate monitoring for signs and symp-
toms of infection is required before and during treatment.
While other adverse events have been reported at rela-
tively low rates, careful monitoring of patients on these
new biologic agents is quite important.
Alefacept
Another biologic agent in development for PsA is ale-
facept, which was approved in the US for the treatment of
psoriasis in 2003. Alefacept is a human LFA-3/IgG1 fusion
protein and is under clinical investigation for the treat-
ment of PsA and RA. The LFA-3 portion of alefacept binds
to CD2 receptors on T cells to block the natural interac-
tion between LFA-3 on antigen-presenting cells and CD2
on T cells. Blockade of the LFA-3/CD2 interaction, a key
co-stimulatory pathway, can inhibit T-cell activation. The
IgG1 portion of alefacept can bind to FcγRIII (CD16) IgG
receptors on accessory cells (e.g. natural killer cells) and
may induce granzyme-mediated apoptosis [52,72].
Alefacept was evaluated as a treatment for psoriasis in
multicenter, randomized, placebo-controlled, double
blind study. Two hundred twenty-nine patients with
chronic psoriasis received intravenous injection of ale-
facept at different dosages. The mean reduction in the
PASI score 12 weeks after treatment was greater in the ale-
facept groups than the placebo group [73].
A small study suggested that alefacept may also improve
both skin and joint symptoms in PsA [74]. In a single
center open-label study, 11 patients with PsA received
intravenous 7.5 mg alefacept once weekly for 12 weeks.
Synovial tissue biopsies of an index joint were obtained
by arthroscopy at baseline and at weeks 4 and 12. Clini-
cally, some degree of improvement in arthritis was
observed in six patients (55%) at the completion of the
treatment. A similar proportion of patients achieved 50%
amelioration of skin disease. This study supports the
notion that T cell activation plays an important role in
chronic inflammatory diseases and effective blockade of
the LFA-3/CD2 interaction may be useful for treating PsA.
Additionally, a double blind, placebo controlled trial
assessed the combination of alefacept and methotrexate
in 185 PsA patients. An ACR20 response was achieved by
54% of the alefacept group versus 24% of the placebo
group. 53% of the alefacept group achieved PASI50 com-
pared with 17% of the placebo group [75]. Adverse events
in this trial occurring at >5% included: back pain,
nasopharyngitis, nausea, URI and increased ALT. There
were no serious infections and the serious adverse event
rate was 2% [76].
Efalizumab
Leukocyte function associate antigen-1 (LFA-1) is an
adhesion molecule expressed on T lymphocytes. It inter-
acts with its ligand, intercellular adhesion molecule
(ICAM-1), in ways that may be relevant to the pathogene-
sis of psoriasis including: stabilizing the binding of anti-
gen-presenting cells to T lymphocytes, facilitating
migration of T lymphocytes from circulation into skin,
and activation of T lymphocytes [77]. Efalizumab is a
humanized monoclonal IgG antibody that binds to the
alpha-subunit (CD11) of LFA-1 and prevents LFA-1 bind-
ing to ICAM-1. In two recent phase 3, randomized, dou-
ble-bind, placebo-controlled trials, efaluzimab showed
efficacy in treating moderate to severe plaque psoriasis,
and was recently approved for this use by the US FDA.
Leonardi et al, reported a study of 498 psoriasis patients
that showed PASI75 scores at 12 weeks in the treatment
groups were achieved in 32.6% of patients versus 2.4% of
placebo-treated patients [77]. The most common adverse
events (headache, fever, chills, nausea, and myalgias)
were more frequent in the efalizumab-treated group only
during the first two injections, and then decreased to rates
similar to placebo. A second study randomized 556 pso-
riasis patients for twelve weeks with continuation in an
open label study [78]. At 12 weeks, PASI50/75 were
58.5%/26.6% respectively in efaluzimab-treated patients
compared with 13.9%/4.3% in placebo treated patients.
These numbers increased at week 24. Patient reported out-
comes (dermatology life quality index and itching scale)
also improved. Interestingly, during the second twelve
weeks there was an increased incidence of arthritisJournal of Immune Based Therapies and Vaccines 2005, 3:6 http://www.jibtherapies.com/content/3/1/6
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(5.6%); 12 of these 19 cases had had a prior history of
arthritis.
Preliminary results from a phase II study of efalizumab in
117 PsA patients showed that treatment did not reach sta-
tistical significance as far as achieving an ACR20 reponse
at twelve weeks [79].
Other types of biologic agents and future directions
The introduction of TNF-α inhibitors and their tremen-
dous clinical impact has generated considerable interest
in exploring other avenues for the treatment of PsA. In
addition, it is worth noting that despite the tremendous
success achieved in PsA patients treated with TNF-α inhib-
itors, approximately one-third of patients with moderate
to severe PsA have negligible or insufficient responses to
such treatment. This has provided the impetus for the
development of biologic agents targeting other aspects of
the dysregulated immune system. Several promising bio-
logic agents, directed at targets other than TNF-α, are cur-
rently under study (Table 1).
One approach is the targeting of other inflammatory
mediators. ABXIL-8 (Abgenix Inc, Fremont, CA), a human
anti-IL-8 monoclonal antibody, binds free IL-8 and may
deactivate it in the skin. Effects of IL-8 include T cell and
neutrophil activation and chemotaxis, as well as keratino-
cyte proliferation. IL-8 may also play a role in the vascular
responses found in psoriasis [80]. A phase II trial in pso-
riasis showed some improvement in patients' PASI as well
as in histological responses [81]. IL-1, many of the activi-
ties of which overlap with TNF, has been suggested to be
of potential importance in the pathogenesis of joint and
other inflammation [82]. Anakinra (IL-1ra) a homologue
of the naturally occurring IL-1 receptor antagonist, has
been approved for use in moderate to severely active RA.
Other IL-1 inhibiting agents are in development. To date
there have not been controlled clinical trials of IL-1 inhib-
itors in PsA.
Another approach that would suppress inflammation
involves the therapeutic use of anti-inflammatory
cytokines. For example, among its various activities, Il-10
inhibits INF-γ and promotes TH2 biased cytokine secre-
tion. IL-10 is relatively deficient in psoriatic skin,
although it is found in high levels in synovium and serum
of PsA patients [83]. Recombinant IL-10 (rIL-10) was used
in a phase II trial in 14 patients with chronic plaque pso-
riasis; 71% had more than a 50% reduction of PASI scores
[84]. It has also been studied in PsA which showed mod-
est improvements in skin but not articular disease [85].
Recombinant human IL-11 (rhIL-11) has been shown to
have anti-inflammatory activity in vitro and in vivo and
has been tested in 12 patients with psoriasis. They showed
some improvement in PASI scores [86]. However, there
are no published reports of it being used in PsA.
Another therapeutic strategy is to target the number or
function of immunocompetent cells central to the propa-
gation of the disease. Several therapies have targeted T
cells, which have been suggested to play a central role in
orchestrating the immune driven inflammation in PsA.
Daclizumab, a humanized antibody to the α-subunit of
the IL-2 receptor, blocks the binding of IL-2, a vital growth
Table 1: Biologic agents under consideration for the treatment of Psoriatic arthritis
Suppression of inflammatory mediators
target agent comment
IL-1 Anakinra IL-1 receptor antagonist
IL-8 ABXIL-8 human anti-IL-8 mAb
Modulation of the function of Anti-inflammatory mediators
target agent comment
IL-10 rIL-10 recombinant human Th2 cytokine
IL-11 rIL-11 recombinant human Th2 cytokine
Alteration of T cell number and function interaction
target agent comment
IL-12 anti-IL-12 mAb several in development
CD25 (IL-2 receptor) Daclizumab humanized anti-CD25 mAb
CD2 Alefacept human LFA-3/IgG fusion protein
CD11a (LFA-1) Efalizumab humanized anti-CD11a mAb
TCR/CD3 huOKT3γ1(ala-ala) humanized anti-CD3 mAb
CD80/CD86 IDEC-114 humanized anti-CD80 mAb
CTLA4Ig fusion protein of CTLA-4/Ig
CD40/CD40L IDEC-131 humanized anti-CD154 mAb
mAb, monoclonal antibody; rIL, recombinant interleukin; IL-2R, LFA, leukocyte function associated antigen; TCR, T-cell receptor; CTLA4Ig, 
cytotoxic T-lymphocyte-associated antigen 4/immunoglobulinJournal of Immune Based Therapies and Vaccines 2005, 3:6 http://www.jibtherapies.com/content/3/1/6
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factor for T cells. One trial in 19 psoriatic patients showed
IL-2 blockade during the first 4 weeks and variable desat-
uration after that, which correlated with reversal in disease
improvement that had been achieved. Patients with pre-
treatment PASI score of <36 showed mean reduction in
severity by 30% at eight weeks [87]. HuOKT3γ1 (ala-ala),
a non-FcR-binding monoclonal antibody to CD3 (a com-
ponent of the T cell receptor complex), modulates the
function of T cells without decreasing their numbers. A
phase I/II study in seven patients with PsA showed 6/7
achieving ACR70 responses at 30 days and all seven had
transient, dose dependent depletion of T cells [88]. CD28
is a cell-surface protein on mature T cells and binds to two
ligands, CD80 and CD86 on antigen-presenting cells.
Blocking this interaction results in incomplete T cell acti-
vation. CTLA-4, a natural inhibitor of CD28, binds to
CD80/86 molecules with high affinity and competes with
CD28. CTLA-4-immunoglobulin (CTLA4Ig) was devel-
oped to block the CD 28 and CD80/86 interactions. A
phase 1 trial in psoriasis patients showed dose dependent
improvement in skin involvement [89]. A CTLA-4-Ig con-
struct, abatacept, is in late phase development for the
treatment of RA. It will likely be studied in PsA in the near
future. IDEC-114, a humanized anti-CD80 monoclonal
antibody, has also been developed to block this interac-
tion. A phase I/II trial of IDEC-114 in 35 psoriatic patients
showed 40% of patients achieved PASI50 [90]. Finally,
therapies directed at inhibiting IL-12, a cytokine central in
driving Th1 biased immune responses, are in the early
phases of investigation in psoriasis and PsA.
Conclusion
Appreciation of the unmet clinical need for affected
patients, greater understanding of the underlying immun-
opathophysiology of this common autoimmune disease,
and progress in biopharmaceutical development have
paved the way for the development of novel biologic
agents for PsA. Following closely upon the successes
achieved in RA, there have been dramatic clinical efficacy
achieved with TNF inhibitors. Substantial improvements
have been noted not only as far as the signs and symptoms
of arthritis, but also in dactylitis and enthesitis and in skin
involvement. Moreover, improvements in functional sta-
tus and quality of life, and attenuation in the progression
of radiographic damage have been achieved. Driven by
this success, biologic agents targeting other components
of the dysregulated immune response that play major
roles in pathogenesis of PsA are actively under study. In
the foreseeable future, we can expect further exciting
development in immunomodulatory therapies for psori-
atic arthritis.
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